Advances in Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma
Ibrutinib Monotherapy
GS-9973 and Idelasib in Patients With R/R CLL
ABT-199 in Patients With R/R CLL/SLL
ABVD With and Without Bleomycin and/or Dacarbazine
Brentuximab Vedotin Followed by ABVD in Patients With Untreated
NHL
Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma
Follicular Lymphoma
Prognostic Value of PET-CT After FL Therapy in FL
FOLL05, 5-Year Follow-up
Alliance/CALGB 50803Lenalidomide Plus Rituximab for Untreated
FL
ROMULUSPolatuzumab Vedotin or Pinatuzumab Vedotin
Plus Rituximab in Patients With R/R FL
Diffuse Large B-Cell Lymphoma
Two Different R-CHOP Variants
ABT-199 for DLBCL
Monitoring MRD Using Cellular and Acellular Blood DNA
Mantle Cell Lymphoma
R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed
Patients With MCL
Subcutaneous Bortezomib in Relapsed MCL
Safety of Ibrutinib in R/R MCL
Alisertib for PTCL
Response to Romidepsin by Number of Lines of Prior Therapies
in R/R PTCL
Topical SHP-141 for CTCL
Outcomes of Patients With PTCL From the BCCA Registry After
Standard Chemotherapy
Abbreviations (cont)
Abbreviations (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)